Core Viewpoint - The Hainan Free Trade Zone concept is experiencing a rebound, with several companies in the sector seeing significant stock price increases, indicating renewed investor interest in this market [1] Company Performance - Caesar Travel (000796) reached its daily limit increase in stock price [1] - Antong Holdings (600179) and Hainan Development (002163) also hit their daily limit increases previously [1] - Other companies such as Haima Automobile (000572), Xinlong Holdings (000955), Hainan Airport (600515), and Hainan Haiyao (000566) showed upward movement in their stock prices [1]

每日经济新闻 每经AI快讯，12月24日，海南自贸区板块短线走低，海南海药跌超6%，中钨高新、罗牛山、康芝药 业、海南橡胶等跟跌。 ...

Group 1 - The Hainan Free Trade Zone sector experienced a short-term decline, with Hainan Haiyao falling over 6% [1] - Other companies such as Zhongtung High-tech, Luoniushan, Kangzhi Pharmaceutical, and Hainan Rubber also saw declines [1]

编辑 王进雨 新京报贝壳财经讯 12月23日，海南海药公告，本次解除限售股份数量为1.31亿股，占公司股份总数的 10.08%。本次解除限售股份可上市流通日期为2025年12月26日。 ...

Core Viewpoint - On December 23, a total of 17 stocks appeared on the trading list, with 8 stocks showing significant activity from the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connects [1] Group 1: Net Buying Stocks - The stocks with the highest net buying amounts included Guojijinggong (国机精工) with a net purchase of 238 million yuan, followed by Hainan Haiyao (海南海药) with 130 million yuan, Aerospace Power (航天动力) with 115 million yuan, and Hongda Electronics (宏达电子) with 100 million yuan [1] Group 2: Net Selling Stocks - The stocks with the highest net selling amounts were Tongyu Communication (通宇通讯) with a net sale of 92.81 million yuan, followed by Yingweike (英维克) with 36.31 million yuan, and Yidong Electronics (奕东电子) with 28.71 million yuan [1]

每经AI快讯，海南海药（SZ 000566，收盘价：8.76元）12月23日晚间发布公告称，公司限售股份约1.31 亿股将于2025年12月26日解禁并上市流通，占公司总股本比例为10.08%。 2025年1至6月份，海南海药的营业收入构成为：医药占比78.45%，医疗服务费占比18.6%，其他业务占 比2.95%。 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 （记者 曾健辉） 截至发稿，海南海药市值为114亿元。 ...

每经AI快讯，12月23日，海南海药（000566）(000566.SZ)公告称，公司2016年度非公开发行限售股份 1.31亿股将于2025年12月26日上市流通，占公司总股本的10.08%。 ...

Core Viewpoint - The official launch of the Hainan Free Trade Port's full island customs operation on December 18, 2025, marks a significant milestone in China's reform and opening-up, aiming to create a highly convenient business environment with policies characterized by "one line open, one line controlled, and free movement within the island" [2][5]. Group 1: Strategic Significance - Hainan Free Trade Port construction provides a Chinese solution for global economic cooperation amidst globalization challenges, exploring a system that aligns with international high-standard economic and trade rules [6]. - The design of "one line open, one line controlled" positions Hainan as a "converter" between domestic and international markets, facilitating the introduction of advanced international production factors to support domestic industrial upgrades [7]. - Hainan's development is expected to strengthen regional cooperation with areas like the Guangdong-Hong Kong-Macao Greater Bay Area, enhancing collaboration with inland provinces and creating a new pattern of coordinated development [8]. - Hainan aims to become a source of national innovation by focusing on future industries such as seed industry, deep sea, aerospace, green, and digital economy [9]. Group 2: Policy Benefits - The scope of "zero tariff" has significantly expanded, with the proportion of zero-tariff items increasing from 21% to 74%, covering approximately 6,600 tariff items, which lowers import and operational costs for enterprises [10]. - A "double 15%" tax incentive is available for eligible enterprises and core talents, offering a competitive income tax rate of 15%, alongside visa-free entry for 86 countries [11]. - The increase in duty-free shopping limits and the expansion of duty-free categories enhance consumer access to quality imported goods [12]. - Trade facilitation policies will benefit sectors such as tourism, aviation, logistics, and duty-free industries, marking a shift towards a system-oriented openness in China's economic model [13]. Group 3: Beneficiary Companies - **Duty-Free Consumption**: China Duty Free Group (601888) is expected to benefit directly from the expansion of duty-free policies, with significant revenue contributions from Sanya International Duty-Free City [14]. - **Transportation and Logistics**: Hainan Airport (600515) operates two major international airports, with a high international route coverage, while Hainan Highway (600238) is involved in key infrastructure projects [17][18]. - **Infrastructure and Manufacturing**: Hainan Ruize (002596) anticipates a 25% increase in construction orders due to the customs operation, while Jinpan Technology (688676) benefits from tax incentives and infrastructure projects [19]. - **Healthcare**: Kangzhi Pharmaceutical (300086) is positioned to accelerate the approval of innovative medical products, while Hainan Haiyao (000566) benefits from reduced R&D costs due to zero tariffs [21][22]. - **New Energy and Advanced Manufacturing**: Haima Automobile (000572) is transitioning to new energy vehicles, benefiting from reduced equipment costs and tax incentives [23]. - **Other Specialty Enterprises**: Hainan Rubber (601118) and Hainan Mining (601969) are expected to see growth in exports and resource development opportunities due to the Free Trade Port's establishment [24][25].

证券代码：000566 证券简称：海南海药 公告编号：2025-080 海南海药股份有限公司 关于 2016 年度非公开发行限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次解除限售股份数量为 130,825,900 股，占公司股份总数的 10.08%。 2、本次解除限售股份可上市流通日期为 2025 年 12 月 26 日。 一、本次解除限售股份的基本情况及公司股本变化情况 （一）本次解除限售股份的基本情况 经中国证券监督管理委员会《关于核准海南海药股份有限公司非公开发行股票的批 复》（证监许可[2016]1353号）核准，海南海药股份有限公司（以下简称"公司"）非 公开发行245,298,400股人民币普通股（A股），发行价格为12.23元/股，于2016年9月12 日在深圳证券交易所上市，本次非公开发行股票完成后，公司总股本由 1,090,680,864 股增加至 1,335,979,264 股。其中，本次非公开发行股票深圳市南方同正投资有限公司 （以下简称"南方同正"）获配股数130,825,900股，限 ...

国海证券股份有限公司 关于海南海药股份有限公司 非公开发行股票限售股解除限售上市流通的核查意见 国海证券股份有限公司（以下简称"国海证券"或"保荐人"）作为海南海 药股份有限公司（以下简称"海南海药"、"上市公司"或"公司"）非公开发 行 A 股股票的保荐人，根据《证券发行上市保荐业务管理办法》、《深圳证券 交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号—主 板上市公司规范运作》等相关法律、法规和规范性文件的规定，对海南海药非公 开发行股票限售股解除限售上市流通的事项进行了审慎核查，具体核查情况如下： 一、本次解除限售股份取得的情况 （一）本次解除限售股份的基本情况 经中国证券监督管理委员会《关于核准海南海药股份有限公司非公开发行股 票的批复》（证监许可[2016]1353 号）核准，海南海药非公开发行 245,298,400 股人民币普通股（A 股），发行价格为 12.23 元/股，于 2016 年 9 月 12 日在深圳 证券交易所上市，本次非公开发行股票完成后，公司总股本由 1,090,680,864 股 增加至 1,335,979,264 股。其中，本次非公开发行股票深圳市南方同 ...